Search PubMed⌕ Search

Biomedical subjects

Giorgio Barbarini

Publications and source records attributed to Giorgio Barbarini.

3 recordsLinked to original sources

Kawasaki-like syndromes and other vasculitic syndromes in HIV-infected patients.

Excluding drug-related hypersensitivity reactions, vasculitic syndromes are not common in HIV-positive patients. Review of the existing literature suggests that HIV positive patients may be predisposed to polyarteritis nodosa, microscopic polyarteritis, Kawasaki-like syndromes, acute occlusion syndromes, primary angiitis of the central nervous system and erythema elevatum diutinum. With the exception of erythema elevatum diutinum, these vasculitic syndromes have significant morbidities and mortality if they are not treated. It is therefore important to make these diagnoses and to initiate appropriate therapy in a timely fashion. Because fevers, malaise, weakness, rashes, headaches and neurologic symptoms are common in HIV-positive patients, it is probable that some cases of vasculitis go undiagnosed. In this report, we review vasculitic syndromes seen in HIV-positive patients. We also re-examine a previously published case of a young HIV-positive male who died of an acute myocardial infarction without atherosclerotic disease. Immunohistopathology of the affected arteries suggests that he died of a Kawasaki-like syndrome.

AIDS-Related Opportunistic Infections↗

Consensus interferon for chronic hepatitis C patients with genotype 1 who failed to respond to, or relapsed after, interferon alpha-2b and ribavirin in combination: an Italian pilot study.

OBJECTIVE: To evaluate the long-term efficacy of consensus interferon in the treatment of chronic hepatitis C patients with genotype 1 who failed to respond to, or relapsed after, combination therapy with interferon alpha-2b and ribavirin. DESIGN: Open label pilot study. METHODS: Twenty-four chronic hepatitis C outpatient non-responders to (12 cases), or relapsers after (12 cases), standard combination therapy were treated with consensus interferon (9 microg five times per week) for 36 weeks. The patients were followed up for a further 24 weeks. The primary end-point of the study was the rate of sustained virological response. RESULTS: Sustained virological response was observed in 33% of previous non-responders and in 42% of previous relapsers. Improvement of the histological score was documented in 80% of previous non-responders and in all previous relapsers who showed undetectable levels of hepatitis C virus RNA at the end of treatment. Logistic regression analysis showed that sustained virological response was associated with a hepatitis C viral load of 2 x 106 copies/ml or less, with an inflammation score of 7 or less and with an estimated duration of disease of 10 years or less. The treatment was well tolerated with an 83% compliance. CONCLUSIONS: Consensus interferon given at a dose of 9 microg five times per week for 36 weeks may offer a good chance of sustained virological response in a subset of patients who failed to respond to, or relapsed after, standard combination therapy. However, a larger randomized trial is required to assess the efficacy of consensus interferon before its use can be advocated for the treatment of such patients.

Adult↗